#Sweden #Stockholm #RaySearch #DrugLog #Medim

RaySearch Laboratories Receives First DrugLog Order

RaySearch Laboratories AB (publ), a prominent player in the medical technology sector, is excited to announce that Medim, a Polish healthcare company, has placed the inaugural order for its innovative product, DrugLog™. This order is particularly significant as it is the result of Medim winning a tender from The Children's Memorial Health Institute, the largest and one of the most well-equipped pediatric hospitals in Poland.

What is DrugLog?

DrugLog is designed to provide a cost-effective solution for the swift and accurate verification of compounded injectable medications. This is essential in treatments like chemotherapy, where precision is critical. By detecting errors in the preparation of drugs, DrugLog significantly reduces the likelihood of medication errors, ensuring a safer treatment environment for patients. The technology combines advanced software with dependable and established hardware that utilizes absorption spectroscopy.

The Importance of the New Order

In a statement, Johan Löf, founder and CEO of RaySearch, expressed his enthusiasm for the order, noting that this represents a strategic step forward for the company. The addition of DrugLog to their offerings bolsters their commitment to supporting a comprehensive range of cancer treatment modalities, including both chemotherapy and surgical interventions.

The order from Medim does not only cover the DrugLog system itself; it also includes support agreements that will extend into the following years. This further ensures that The Children's Memorial Health Institute will have ongoing assistance and reliability in using the product.

A Partnership Built on Experience

Medim was established in 1990 and boasts extensive experience in delivering varied solutions to the healthcare sector, particularly in the Polish market. Their expertise and deep understanding of industry needs have positioned them well as a trusted partner for RaySearch. Mateusz Nejman, the Director of New Technologies at Medim, articulated the significance of this partnership for both companies. He stated, "This is an important milestone for our partnership with RaySearch. The new customer is a proof of how our joint efforts and expertise create concrete results in the market."

This strategic collaboration is not new; it builds on a foundation of mutual expertise aimed at enhancing healthcare outcomes. DrugLog's introduction into the market is poised to provide significant benefits, particularly in pediatric care, where the stakes are often higher and the need for precision is paramount.

Future Directions

The acquisition of DrugLog by RaySearch from Pharmacolog in Uppsala, Sweden, earlier in 2024 was geared towards complementing their portfolio by offering improved solutions for quality assurance in cancer treatments that utilize cytostatic drugs.

The potential implications of DrugLog go beyond immediate operational efficiencies—it signifies a commitment to improving patient safety and care quality on a broader scale. As RaySearch continues to innovate and expand its offerings, DrugLog stands out as a critical tool in their mission to enhance healthcare outcomes through technology.

The Bigger Picture

In conclusion, RaySearch's successful venture into this partnership marks a pivotal moment in their journey towards promoting safer healthcare practices. By effectively aligning their innovations with the needs of leading healthcare institutions like The Children's Memorial Health Institute, RaySearch signifies its intent to be a cornerstone in the future of cancer treatment solutions.

For additional information on RaySearch Laboratories and its innovative products, including DrugLog, please contact Johan Löf via telephone at +46 (0) 8 510 530 00, or explore the company’s social media channels for more insights.

Learn more about RaySearch and their mission to enhance cancer treatment through technological innovation.